You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Platinum-based chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Cancer, Ototoxicity, Drug-Induced, Quality of Life Trial (Patients suffering from chemo-induced ototoxicity)

Not yet recruiting
  • Cancer
  • +3 more
  • Patients suffering from chemotherapy-induced ototoxicity
  • (no location specified)
Jun 29, 2023

NSCLC Trial in Worldwide (RO7247669, Pembrolizumab, Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Benowa, Queensland, Australia
  • +6 more
Mar 16, 2023

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Non Small Cell Lung Cancer, Propranolol Trial (Propranolol HCl, Sintilimab, Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Propranolol
  • Propranolol hydrochloride
  • +2 more
  • (no location specified)
Jul 31, 2023

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,

Terminated
  • Advanced Solid Tumor
  • +3 more
  • Darlinghurst, New South Wales, Australia
  • +1 more
Dec 18, 2022

Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)

Not yet recruiting
  • Cervical Cancer
  • TQB2868 injection
  • +4 more
  • Chongqing, Chongqing, China
  • +1 more
Aug 17, 2023

Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)

Recruiting
  • Cholangiocarcinoma
  • Novel combination of chemotherapy and immunotherapy
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jul 28, 2022

Toripalimab, First-line Treatment Trial in Guangzhou (EP/EC+PD-1)

Recruiting
  • Toripalimab
  • First-line Treatment
  • Guangzhou, Guangdong, China
    Sun Yat-sen University cancer center
Mar 7, 2023

NSCLC Trial (QL1706 injection, Vinorelbine Tartrate, Paclitaxel)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • QL1706 injection
  • +6 more
  • (no location specified)
Aug 3, 2022

Non Small Cell Lung Cancer Trial in Changsha (IBI-322 Plus Lenvatinib and Platinum)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • IBI-322 Plus Lenvatinib and Platinum
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 14, 2022

Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Jun 5, 2023

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

NSCLC Trial (Durvalumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Jun 22, 2023

Pembrolizumab Combined With Double Platinum Based Chemotherapy

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Feb 28, 2022

    Chemotherapeutic Toxicity Trial (Home Based Walking Program)

    Not yet recruiting
    • Chemotherapeutic Toxicity
    • Home Based Walking Program
    • (no location specified)
    Aug 28, 2023

    Non Small Cell Lung Cancer Trial in Changsha (Atezolizumab)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer hospital
    May 19, 2022

    NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

    Active, not recruiting
    Has Results
    • Non-small Cell Lung Cancer
    • pembrolizumab
    • +3 more
    • (no location specified)
    Aug 18, 2022

    Patients With Advanced Treatment Naive LCNEC Trial in Tel Aviv (Durvalumab)

    Recruiting
    • Patients With Advanced Treatment Naive LCNEC
    • Tel Aviv, Israel
      Assuta MC
    Feb 20, 2022

    Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

    Not yet recruiting
    • Non-squamous Non-small-cell Lung Cancer
    • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
    • +2 more
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    May 5, 2023

    Cervical Cancer Trial in Hong Kong (Avelumab, Axitinib)

    Recruiting
    • Cervical Cancer
    • Hong Kong, Hong Kong
      The University of Hong Kong
    Feb 23, 2022

    NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

    Active, not recruiting
    Has Results
    • Non-small Cell Lung Cancer
    • pembrolizumab
    • +3 more
    • (no location specified)
    Aug 18, 2022